As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.
19 Analysts have issued a Scholar Rock Holding Corp. forecast:
19 Analysts have issued a Scholar Rock Holding Corp. forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -322 -322 |
55%
55%
|
|
| EBIT (Operating Income) EBIT | -323 -323 |
54%
54%
|
|
| Net Profit | -316 -316 |
55%
55%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative medicines. The company offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.
| Head office | United States |
| CEO | David Hallal |
| Employees | 128 |
| Founded | 2012 |
| Website | scholarrock.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


